Form 4: ASMB CMO Anuj Gaggar Receives RSU Grant

Assembly Biosciences' Chief Medical Officer, Anuj Gaggar, was granted 26,000 restricted stock units, with a portion contingent on stockholder approval.

Summary

• Anuj Gaggar, Chief Medical Officer of Assembly Biosciences, Inc. (ASMB), was granted 26,000 restricted stock units (RSUs) on March 29, 2026.
• These RSUs vest in four equal installments annually, starting March 29, 2027, and continuing through March 29, 2030, subject to continuous service.
• The 26,000 RSUs represent 65% of the annual equity grant.
• The remaining 35% of the annual equity grant is contingent upon stockholder approval of an amendment to the 2018 Stock Incentive Plan to increase the number of shares authorized for issuance.
• Following this transaction, Gaggar beneficially owns 28,000 shares, which includes 2,000 shares acquired under the Employee Stock Purchase Plan on November 14, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the executive retention aspect of the RSU grant, though the contingency on stockholder approval for the full grant introduces a minor element of uncertainty.

Positives

• The grant of restricted stock units serves as an incentive for the Chief Medical Officer, Anuj Gaggar, to remain with Assembly Biosciences, promoting executive retention.
• Equity compensation aligns management's interests with those of shareholders by tying a portion of their compensation to the company's stock performance.

Negatives

• A portion (35%) of the Chief Medical Officer's annual equity grant is contingent on stockholder approval of an amendment to the 2018 Stock Incentive Plan, introducing uncertainty regarding the full intended grant.
• The issuance of new shares for equity grants can lead to minor dilution for existing shareholders, although the immediate impact from this specific grant is likely small.

Risks

• The full annual equity grant to the Chief Medical Officer is subject to the risk of not receiving stockholder approval for an amendment to the 2018 Stock Incentive Plan, which would increase the number of shares authorized for issuance.

Future Outlook

The vesting schedule for the restricted stock units extends through March 29, 2030, indicating a long-term incentive structure. The completion of the full annual equity grant is contingent on future stockholder approval of an amendment to the 2018 Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units (RSUs), are a standard component of executive compensation packages across the biotechnology and pharmaceutical industries. These grants are designed to attract, retain, and motivate key personnel by aligning their financial interests with long-term shareholder value creation. The contingency on stockholder approval for a portion of the grant is also a common practice when companies need to replenish their share pools for incentive plans.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a widely adopted practice, comparable to companies like Moderna (MRNA) or BioNTech (BNTX), which frequently utilize equity awards to incentivize their scientific and executive leadership.
• The multi-year vesting schedule (four equal installments over four years) is a standard approach to promote long-term retention and performance, similar to vesting schedules seen at major biotech firms.
• The requirement for stockholder approval to increase the authorized share pool for incentive plans is a common corporate governance practice, ensuring shareholder oversight on potential dilution, mirroring practices at companies across various sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution if the full RSU grant is issued, but also benefit from executive retention and alignment of management interests. Will need to vote on the plan amendment.
• Employees: The Employee Stock Purchase Plan (ESPP) mentioned indicates a broader program for employee equity participation.
• Management (Anuj Gaggar): Receives significant equity incentive, contingent on performance and company longevity.

Next Steps

• Stockholders will need to vote on an amendment to the 2018 Stock Incentive Plan to increase authorized shares for the remaining 35% of the annual equity grant.
• Anuj Gaggar's RSUs will vest in four equal installments on March 29, 2027, 2028, 2029, and 2030, assuming continuous service.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of an executive equity grant and does not contain information that would typically warrant a change in investment recommendation. It reflects standard executive compensation practices aimed at retention and alignment of interests, which is generally neutral to slightly positive for long-term stability but not a catalyst for immediate price movement.

Keywords

Assembly Biosciences, ASMB, Form 4, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, Anuj Gaggar, Chief Medical Officer, Stock Incentive Plan